Related Experiment Videos
Estramustine phosphate (Estracyt) in the treatment of prostatic carcinoma
1Pharmacia-LEO Therapeutics AB, Helsingborg, Sweden.
International Urology and Nephrology
|January 1, 1989
Abstract:
This review presents the most important hormonal, cytotoxic and pharmacokinetic properties of estramustine phosphate. Furthermore the results of randomized Phase III trials are described in patients with hormone refractory prostatic cancer with and without previous irradiation. Several randomized studies are reported with Estracyt also in the primary treatment of this disease.